Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum SQI Diagnostics Inc V.SQD.H

SQI Diagnostics Inc. is a Canada-based company that is focused on lung health. The Company is engaged in the development and manufacturing of respiratory health and precision medicine tests that run on its fully automated systems. Its clinical solutions include Rapid Acute Lung Injury Diagnostic (RALI-Dx), lung transplant diagnostics, COVID-19 testing and surveillance testing solutions. Its... see more

TSXV:SQD.H - Post Discussion

SQI Diagnostics Inc > Hot off the press - is it a start.....we'll see....
View:
Post by FactFinder1994 on Apr 21, 2021 2:45pm

Hot off the press - is it a start.....we'll see....

COVID & Healthcare Conference Reunion - A Year in Review

 
RSVP
April 22nd, 2021 - Start Time: 4:15pm ET
 
Join Adelaide Capital on April 22nd at 4:15pm ET for a throwback BYOB to hear how these Canadian companies have helped shape the global response to the pandemic over the past year. We are also thrilled that Eden Rahim, CIO of Next Edge Capital agreed to return once again to give an overview on investing in healthcare during these tumultuous times.

Almost one year ago we hosted our first virtual conference, COVID & Healthcare, where we showcased several small cap Canadian healthcare companies that responded quickly to the newly emerging pandemic and were already developing COVID related products, treatments, and therapies. We have followed their progress over the past year and thought it was fitting to invite a few back for an update, a Q&A and maybe even a virtual cocktail or two.

We are hosting this event in support of Team Tina Byers’ fundraiser for the Leukemia & Lymphoma Society of Canada. One of the themes we have seen over the course of the pandemic is the lack of funding, research, diagnosis, and treatment for other life-threatening illnesses. Leukemia & Lymphoma is one close to our hearts, so we ask that anyone that is able to make a donation considering doing it in support of Team Tina Byers here: https://bit.ly/3r93cut.

Keynote: Eden Rahim, Portfolio Manager, Next Edge Capital
Eden Rahim is the Portfolio Manager for the Next Edge Biotech and Life Sciences Opportunities Fund. Eden’s broad experience includes over twenty-five years as a Portfolio and Hedge Fund Money Manager, Options Strategist, Derivatives & Biotech Analyst.
 
Eden possesses a top quartile 5-year 5-Star growth fund Portfolio Manager track record on over $1 billion in assets across 4 mandates at RBC Global Asset Management, in addition, Eden has delivered a +26% compounded annual return across a biotechnology mandate between 1995-2003. His experience also includes overseeing 14 Covered Call ETFs (over $0.7 Billion AUM) in Canada, the US & Australia while at Horizons Exchange Traded Funds.
 
Eden is a regular guest speaker on the biotech industry on Bloomberg TV, BNN, as well as an author and contributor to many industry sources and major press articles in the US, and Canada. He also contributes as a speaker at numerous healthcare conferences.

 

Presenting Companies
Appili Therapeutics (APLI)
Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. As part of a global consortium, Appili is sponsoring late-stage clinical trials evaluating the antiviral Avigan® / REEQONUSTM (favipiravir) for the worldwide treatment and prevention of COVID-19. The Company is also advancing a diverse range of anti-infectives, including a broad-spectrum antifungal, a vaccine candidate to eliminate a serious biological weapon threat, and two novel antibiotic programs. Led by a proven management team, Appili is at the epicenter of the global fight against infection.

Cardiol Therapeutics (CRDL)
Cardiol Therapeutics Inc. is a clinical-stage biotechnology company focused on the research and clinical development of innovative anti-inflammatory therapies for the treatment of cardiovascular disease (“CVD”). The Company’s lead product, CardiolRx™, is a pharmaceutically produced oral cannabidiol formulation that is currently entering a Phase II/III outcomes study in hospitalized patients testing positive for the COVID-19 virus. This potentially registrational trial is designed to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce mortality and major cardiovascular events in COVID-19 patients who have a prior history of, or risk factors for, CVD, and to investigate the influence CardiolRx has on key markers of inflammatory heart disease.

iFabric Corp (IFA)
Headquartered in Markham, Ontario, iFabric Corp offers a variety of products and services two strategic divisions. IFTNA is focused on performance apparel as well as proprietary chemical formulations that render fabrics, foams, plastics and numerous other surfaces intelligent, thereby improving the safety and well-being of the consumer. Its products are used in a wide range of market segments such as healthcare, military, sportswear, and hospitality applications. Coconut Grove, operating as Coconut Grove Intimates, is a designer, manufacturer, distributor, licensor and licensee of ladies intimate apparel products and accessories.

Lexagene Holdings (LXG)
LexaGene is a molecular diagnostics company that develops systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, enter sample ID and press ‘go’. The MiQLab™ system delivers excellent sensitivity, specificity, and breadth of detection and can return results in approximately one hour. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.

Microbix Biosciences (MBX)
Microbix develops proprietary biological technology solutions for human health and well-being, with about 90 skilled employees and sales growing from a base of over $1 million per month. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Microbix antigens enable the antibody tests of over 100 international diagnostics companies, while its QAPs are sold to clinical laboratory accreditation organizations, diagnostics companies, and clinical laboratories. Microbix QAPs are now available in over 30 countries, distributed by 1WA (Oneworld Accuracy Inc.), Alpha-Tec Systems, Inc., D.I.D. Diagnostic Int’l Distribution SpA, Labquality Oy, The Medical Supply Company of Ireland Ltd, R-Biopharm AG, and Seegene Canada Inc. Microbix is ISO 9001 and 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed, and provides CE marked products.

SQI Diagnostics (SQI)
SQI Diagnostics Inc. is a precision medicine company that discovers, develops, and commercializes innovative rapid diagnostic testing for healthcare providers, patients, and consumers worldwide. The Company’s proprietary advanced diagnostics target organ transplant, autoimmune disease and COVID-19 testing which include the developmental direct-to-consumer COVID-19 HOME Antibody Test, the RALI-Dx™ COVID-19 Severity Triage Test and the COVID-19 RALI-fast™ Severity Triage Point-of-Care (POC) Test. SQI’s rapid diagnostic tests are intended to be sold to healthcare professionals so that patients can get accurate results and fast effective treatment, and direct-to-consumers so that individuals can be empowered to improve their health outcomes from the comfort of home. 
SUBSCRIBE TO OUR YOUTUBE CHANNEL SUBSCRIBE TO OUR YOUTUBE CHANNEL
 
 
 
Instagram
LinkedIn
Twitter
YouTube
Website
Want to get in touch? Contact us
Deborah Honig - (647) 203-8793 / deborah@adcap.ca
Victoria Rutherford - (416) 704-4347 / victoria@adcap.ca
Tina Byers - (905) 330-3275 / tina@adcap.ca
Vanessa Bogaert - (604) 721-7773 / vanessa@adcap.ca
Linda Armstrong - (647) 456-9223 / linda@adcap.ca
Baba Hughes - (416) 693-8589 / baba@adcap.ca
Lauren Thompson - (416) 557-7323 / lauren@adcap.ca
Comment by bhikku2 on Apr 22, 2021 5:02pm
Here's today's Adelaide Capital session including the SQI interview: https://www.youtube.com/watch?v=PVCnf20xPuU (still live right now; expecting recording to be available afterward)
Comment by ResearchGuy on Apr 22, 2021 7:24pm
Watched the presentation and it really just confirms that SQI is going to become one of the major players in this new field that we are entering into in regards to precision testing. Not only for COVID and its variants but also for other health issues as mentioned. This will be a year that will certainly propel SQI upward and beyond. GLTA
Comment by mercedesman on Apr 22, 2021 10:20pm
Rob got off to a bit of a slow start and Edam was a bit cheesy ... but overall they did a decent job of laying it out for everyone ... I.e. the next wave of Covid pivoting companies that are set to benefit.... ... hint: it involves diagnostics, antibody detection, serology and home testing.  people need to be able to answer the following questions: Am I still protected by either ...more  
Comment by inspecthrgadget on Apr 22, 2021 10:50pm
He is a fine cheese and usually serves up a few crackers. The rabbit companies that had little meat on the bone have made their run. The honeymoon is over and it is a show me market in the covid space. These guys have the goods, it was better to remain owners and keep positions versus joining the early Cv19 hype. You need to have the goods to wait it out and not just move on a rising tide. A ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities